While IDO inhibitors have already reached clinical trials, they are rather regarded as potential anti-cancer therapeutics; KMO inhibitors that could be of more interest as potential drugs in neurodegenerative diseases are still in the earlier pre-clinical stage of development [49]. Here, IDO1 is linked to neurodegenerative disease.